

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

Specifically:

- Claim 14 has been amended and claim 21 has been added directed towards the deleted subject matter of claim 15.
- Claims 15-17 have been cancelled.
- Claim 18 has been amended and claim 22 has been added directed towards the deleted subject matter of claim 19.
- Claim 23 has been added. Basis for this claim is to be found on page 25 line 1 to page 27 line 17.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101117-1P US.

Respectfully submitted,



Name: Lucy Padget
Dated: December 13, 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451